Interleukin 6: at the Interface of Human Health and Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Oct 16

PMID 37841263

Authors

Elena Grebenciucova

Stephen VanHaerents

Affiliations

Soon will be listed here.

Abstract

Interleukin 6 (IL-6) is a pleiotropic cytokine executing a diverse number of functions, ranging from its effects on acute phase reactant pathways, B and T lymphocytes, blood brain barrier permeability, synovial inflammation, hematopoiesis, and embryonic development. This cytokine empowers the transition between innate and adaptive immune responses and helps recruit macrophages and lymphocytes to the sites of injury or infection. Given that IL-6 is involved both in the immune homeostasis and pathogenesis of several autoimmune diseases, research into therapeutic modulation of IL-6 axis resulted in the approval of a number of effective treatments for several autoimmune disorders like neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis, juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis (GCA), and cytokine release syndrome, associated with SARS-CoV2 pneumonia. This review discusses downstream inflammatory pathways of IL-6 expression and therapeutic applications of IL-6 blockade, currently investigated for the treatment of several other autoimmune conditions such as autoimmune encephalitis, autoimmune epilepsy, as well as myelin oligodendrocyte glycoprotein associated demyelination (MOGAD). This review further highlights the need for clinical trials to evaluate IL-6 blockade in disorders such neuropsychiatric lupus erythematosus (SLE), sarcoidosis and Behcet's.

Citing Articles

Taurine Attenuates Neuronal Ferroptosis by CSF-Derived Exosomes of GABABR Encephalitis Through GABABR/NF2/P-YAP Pathway.

Zhang C, Zhou T, Qiao S, Lu L, Zhu M, Wang A Mol Neurobiol. 2025; .

PMID: 40085353 DOI: 10.1007/s12035-025-04819-3.

Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.

Sahbaz A, Selcuk B, Domac F, Demir S, Koseoglu M, Uludasdemir E Biochem Genet. 2025; .

PMID: 40072812 DOI: 10.1007/s10528-025-11077-4.

Update on tocilizumab in rheumatoid arthritis: a narrative review.

Parisi S, Ditto M, Ghellere F, Panaro S, Piccione F, Borrelli R Front Immunol. 2025; 16:1470488.

PMID: 40066438 PMC: 11891176. DOI: 10.3389/fimmu.2025.1470488.

Hepatic encephalopathy: risk identification and prophylaxis approaches.

Torre A, Cordova-Gallardo J, Martinez-Sanchez F Metab Brain Dis. 2025; 40(3):138.

PMID: 40053146 DOI: 10.1007/s11011-025-01531-y.

Something to talk about; crosstalk disruption at the neurovascular unit during HIV infection of the CNS.

Galpayage Dona K, Benmassaoud M, Gipson C, McLaughlin J, Ramirez S, Andrews A NeuroImmune Pharm Ther. 2025; 3(2):97-111.

PMID: 39958876 PMC: 11823645. DOI: 10.1515/nipt-2024-0003.

References

Feng Q, Wang Y, Yang Y . Neuroprotective effect of interleukin-6 in a rat model of cerebral ischemia. Exp Ther Med. 2015; 9(5):1695-1701. PMC: 4471691. DOI: 10.3892/etm.2015.2363. View

Ye S, Johnson R . Increased interleukin-6 expression by microglia from brain of aged mice. J Neuroimmunol. 1999; 93(1-2):139-48. DOI: 10.1016/s0165-5728(98)00217-3. View

Galea I . The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021; 18(11):2489-2501. PMC: 8481764. DOI: 10.1038/s41423-021-00757-x. View

Atienza-Mateo B, Beltran E, Hernandez-Garfella M, Pascual E, Martinez-Costa L, Atanes A . Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021; 39 Suppl 132(5):37-42. DOI: 10.55563/clinexprheumatol/9ipkcs. View

Quarta S, Baeumer B, Scherbakov N, Andratsch M, Rose-John S, Dechant G . Peripheral nerve regeneration and NGF-dependent neurite outgrowth of adult sensory neurons converge on STAT3 phosphorylation downstream of neuropoietic cytokine receptor gp130. J Neurosci. 2014; 34(39):13222-33. PMC: 4172810. DOI: 10.1523/JNEUROSCI.1209-13.2014. View

Quek A, Britton J, McKeon A, So E, Lennon V, Shin C . Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012; 69(5):582-93. PMC: 3601373. DOI: 10.1001/archneurol.2011.2985. View

Husari K, Labiner K, Huang R, Said R . New-Onset Refractory Status Epilepticus in Children: Etiologies, Treatments, and Outcomes. Pediatr Crit Care Med. 2019; 21(1):59-66. DOI: 10.1097/PCC.0000000000002108. View

Zhang J, Sadowska G, Chen X, Park S, Kim J, Bodge C . Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. FASEB J. 2015; 29(5):1739-53. PMC: 4771067. DOI: 10.1096/fj.14-258822. View

Hanin A, Cespedes J, Dorgham K, Pulluru Y, Gopaul M, Gorochov G . Cytokines in New-Onset Refractory Status Epilepticus Predict Outcomes. Ann Neurol. 2023; 94(1):75-90. DOI: 10.1002/ana.26627. View

10.

Sakuma H, Tanuma N, Kuki I, Takahashi Y, Shiomi M, Hayashi M . Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2014; 86(7):820-2. DOI: 10.1136/jnnp-2014-309388. View

11.

Jun J, Lee S, Kim R, Chu K, Lee S . Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018; 84(6):940-945. DOI: 10.1002/ana.25374. View

12.

San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min C . Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014; 123(26):4136-42. PMC: 4123433. DOI: 10.1182/blood-2013-12-546374. View

13.

Lee W, Lee S, Moon J, Sunwoo J, Byun J, Lim J . Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics. 2016; 13(4):824-832. PMC: 5081109. DOI: 10.1007/s13311-016-0442-6. View

14.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

15.

Maver A, Medica I, Salobir B, Sabovic M, Tercelj M, Peterlin B . Polymorphisms in genes coding for mediators in the interleukin cascade and their effect on susceptibility to sarcoidosis in the Slovenian population. Int J Mol Med. 2007; 20(3):385-90. View

16.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C . Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T17 cells. Nat Immunol. 2016; 18(1):74-85. PMC: 5164931. DOI: 10.1038/ni.3632. View

17.

Clarkson B, LaFrance-Corey R, Kahoud R, Farias-Moeller R, Payne E, Howe C . Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome. Ann Neurol. 2019; 85(4):526-537. PMC: 6450741. DOI: 10.1002/ana.25439. View

18.

Wada-Isoe K, Wakutani Y, Urakami K, Nakashima K . Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol Scand. 2004; 110(2):124-7. DOI: 10.1111/j.1600-0404.2004.00286.x. View

19.

Barabasi B, Barna L, Santa-Maria A, Harazin A, Molnar R, Kincses A . Role of interleukin-6 and interleukin-10 in morphological and functional changes of the blood-brain barrier in hypertriglyceridemia. Fluids Barriers CNS. 2023; 20(1):15. PMC: 9990353. DOI: 10.1186/s12987-023-00418-3. View

20.

Tosato G, Seamon K, Goldman N, Sehgal P, May L, Washington G . Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988; 239(4839):502-4. DOI: 10.1126/science.2829354. View